Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China

Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China

ObjectiveTo assess the potential benefit of chidamide maintenance therapy after induction treatment in peripheral T-cell lymphoma (PTCL).Materials and MethodsThe clinical data of 48 transplantation-ineligible patients with different PTCL subtypes who received continuous chidamide treatment after fir...

Full description

Bibliographic Details
Main Authors:	Wei Guo, Xingtong Wang, Jia Li, Xianying Yin, Yangzhi Zhao, Yang Tang, Anna Wang, Ou Bai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Oncology
Subjects:	chidamide PTCL maintenance therapy ASCT ineligible induction therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.875469/full

Similar Items

Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma
by: Simeng Gu, et al.
Published: (2024-04-01)

Maintenance therapy with chidamide prevents from postoperative recurrence after autologous hematopoietic stem cell transplantation for peripheral T cell lymphoma
by: LIU Hongyun, et al.
Published: (2020-09-01)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
by: Qiang Zeng, et al.
Published: (2023-03-01)

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
by: Shafique MR, et al.
Published: (2018-05-01)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
by: Guang Lu, et al.
Published: (2023-08-01)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
by: Sarah A. Bird, et al.
Published: (2020-05-01)

Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation✰
by: Minh Phuong Vu, et al.
Published: (2023-01-01)

Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?
by: Bahar UNCU ULU, et al.
Published: (2021-08-01)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
by: Yuankai Shi, et al.
Published: (2017-03-01)

How I manage frontline transplant-ineligible multiple myeloma
by: Daniele Derudas, et al.
Published: (2020-09-01)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
by: Jinni Wang, et al.
Published: (2022-02-01)

The Role of Epigenetic Modifier Mutations in Peripheral T-Cell Lymphomas
by: Adrian-Bogdan Tigu, et al.
Published: (2023-11-01)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
by: Mengya Zhong, et al.
Published: (2021-12-01)

Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas
by: Akira Satou, et al.
Published: (2022-08-01)

Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL)
by: Jun Du, et al.
Published: (2023-04-01)

Vemurafenib combined with chidamide promotes senescence of secondary acute myeloid leukemia cells
by: ZHOU Qiao, et al.
Published: (2023-08-01)

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
by: Jinghong Chen, et al.
Published: (2023-02-01)

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
by: Mohammad Jad Moussa, et al.
Published: (2024-02-01)

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer
by: Jieqing Li
Published: (2023-04-01)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
by: Hastono Ridwansyah, et al.
Published: (2023-09-01)

Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy
by: Qingqing Lin, et al.
Published: (2023-08-01)

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
by: Wei Zhang, et al.
Published: (2021-08-01)

Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine
by: Yumeng Zhang, et al.
Published: (2020-06-01)

Synthesis and Crystal Structure Analysis of Histone Deacetylase Inhibitor Chidamide
by: Bo Han, et al.
Published: (2023-06-01)

Chidamide combined with mycophenolate mofetil suppress proliferation of secondary acute myeloid leukemia cells
by: CAI Duo, et al.
Published: (2022-07-01)

Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis
by: Li Z, et al.
Published: (2023-08-01)

Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2‐negative metastatic breast cancer: A real‐world multicenter study
by: Doudou Li, et al.
Published: (2024-02-01)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
by: Wei Zhang, et al.
Published: (2019-05-01)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
by: Rishi Agarwal, et al.
Published: (2012-12-01)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
by: Xinyang Li, et al.
Published: (2022-02-01)

Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells
by: Jinjin Shao, et al.
Published: (2024-04-01)

Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study
by: Xin-Yu Li, et al.
Published: (2023-02-01)

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
by: Wenjiao Tang, et al.
Published: (2024-01-01)

Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up
by: Fang Zhu, et al.
Published: (2020-08-01)

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer
by: Lixia Cao, et al.
Published: (2021-03-01)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
by: Alina Striha, et al.
Published: (2018-03-01)

Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy
by: Zhen Shang, et al.
Published: (2023-10-01)

Identification of potential target genes of breast cancer in response to Chidamide treatment
by: Han Han, et al.
Published: (2022-11-01)

Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
by: Susmita Sharma, et al.
Published: (2018-12-01)

LncRNA ENST869 Targeting Nestin Transcriptional Region to Affect the Pharmacological Effects of Chidamide in Breast Cancer Cells
by: Xiuyan Feng, et al.
Published: (2022-04-01)